A preclinical study has proved the sensitivity to Aurora kinase inhibitors in MYC-driven SCLC, together with chemotherapy.66 Similarly, in another preclinical study, amplification or activation of any one of the three MYC family genes could predict the effects to Aurora kinase inhibitor.67 Here, MYC is linked to small cell lung carcinoma.